Artificial intelligence (AI) is increasingly used in oncology to support tasks such as clinical-trial matching, evidence ...

Daiichi Sankyo and Merck & Co/MSD have withdrawn their U.S. application seeking accelerated approval of ifinatamab deruxtecan ...

Biotech leadership cannot stay static as a company moves from the benchtop to the clinic, writes, CEO of CERo Therapeutics.

Rare cancers can expose a difficult gap between advances in precision oncology and the systems that determine access to ...

For patients with early-stage lung cancer who cannot undergo surgery, precision radiation therapy is the main curative-intent ...

Steven Quay M.D., Ph.D. has served as President and Chief Executive Officer since founding Atossa Therapeutics in 2009. A ...

For many patients with cancer, access to a clinical trial still depends on where the trial is located, not just whether a ...

A Radioactive Bandage Offers a New Brachytherapy Approach for Selected Non-Melanoma Skin Cancers. CivaDerm™ delivers ...

Carboplatin and cisplatin are platinum-based chemotherapies that have been fundamental components of cancer treatment for decades. They are used across multiple malignancies, including lung, ovarian, ...

Sylvester researchers will compare circulating tumor DNA (ctDNA) against standard tissue testing in roughly 490 plasma samples drawn from patients enrolled in PanCAN’s Precision Promise trial network, ...

Medicare's National Coverage Determination 90.2 (NCD 90.2), finalized in 2018, largely reflects a precision oncology landscape built around..

Promising science often fails to become a therapy that reaches patients, and the cause is frequently a strategic business error rather than..